1. A resource allocation system, comprising:
a first network interface;
a database storing information regarding a plurality of items, the information for at least a first of the plurality of items including:
a date for an event at which the first item may be used;
an identifier of a current holder of the first item,
an indicator as to whether the first item has been transferred;
a load balancer;
a web proxy processor configured to selectively block an inbound user browser request or route an inbound user browser request to a destination server;
a cache cluster system configured to cache data and states for access by one or more system components; and
program code stored in a non-transitory computer readable memory, which, when executed by a computing device, is configured to:
store a session identifier on a user terminal associated with a user browser of a first user;
process an acquisition request for an item from the user browser while the user browser is accessing a first website;
transmit to the user browser an indication that the acquisition request is accepted if the acquisition request meets a predefined criterion;
if the acquisition request is accepted, automatically transmit to the browser an offer to transfer the item to another user prior to the user navigating away from the first website;
receive the session identifier from the user terminal;
use the session identifier for identification;
determine if a transfer instruction has been received from the user browser;
at least partly in response to the receipt of the transfer instruction, offer the item to at least one other user; and
transfer the item to a second user if a first criterion is met, wherein the first user is inhibited from using the item after the item is transferred;
wherein the database stores:
an identifier associated with the first user in association with the item;
an identifier associated with the second user in association with the item,
wherein the item is an event ticket,
wherein the program code is further configured to:
provide the event ticket to the user;
inhibit the user’s ability to utilize the event ticket by invalidating the event ticket provided to the user; and
provide a new event ticket to a second user to whom the event ticket is being transferred to, wherein the new event ticket provides the second user the same rights to attend the event as the event ticket provided to the user prior to invalidation.
2. The system as defined in claim 1, wherein the system is configured to provide the offer to transfer at substantially the same time the indication that the acquisition request is accepted is transmitted to the user terminal or substantially immediately thereafter.
3. The system as defined in claim 1, wherein the program code, when executed, is further configured to access an indication as to whether the first user is prohibited from transferring a second item acquired by the first user via the system, wherein the second item is an event ticket, and inhibiting the ability of the first user to transfer the second item at least partly in response to the indication indicating that the first user is prohibited from transferring the second item.
4. The system as defined in claim 1, wherein the program code, when executed, is further configured to:
provide for display via the browser, in association with the offer to transfer, an interface via which the user can specify a price for the item;
determine if the transfer price complies with a first rule; and
transmit for display via the browser a notification if the price does not comply with the first rule.
5. The system as defined in claim 1, wherein the program code, when executed, is further configured to provide the new event ticket to a telephonic device associated with the second user.
6. Program A program code stored in a non-transitory computer readable memory, which, when executed by a computing device, is configured to:
store a session identifier on a user terminal associated with a user browser;
process an acquisition request for an item from the user browser while the user browser is accessing a first website;
transmit to the user browser an indication that the acquisition request is accepted if the acquisition request meets a predefined criterion;
if the acquisition request is accepted, store an identifier associated with the first user in association with the item;
automatically transmit to the browser an offer to transfer the item to another user prior to the user navigating away from the first website;
receive the session identifier from the user terminal;
use the session identifier for identification;
determine if a transfer instruction has been received from the user browser;
at least partly in response to the receipt of the transfer instruction, offer the item to at least one other user; and
transfer the item to a second user if a first criterion is met, wherein the first user is inhibited from using the item after the item is transferred and an identifier associated with the second user is stored in association with the item,
wherein the item is an event ticket,
wherein the program code is further configured to:
provide the event ticket to the user;
inhibit the user’s ability to utilize the event ticket by invalidating the event ticket provided to the user; and
provide a new event ticket to a second user to whom the event ticket is being transferred to, wherein the new event ticket provides the second user the same rights to attend the event as the event ticket provided to the user prior to invalidation.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of the formula:
and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein
one Z2 is CA and the other is CR1, wherein R1 is hydrogen or a noninterfering substituent;
A is \u2014Wi\u2014COXjY wherein Y is COR2 wherein R2 is hydrogen or a noninterfering substituent, each of W and X is a spacer preferably of 2-6\u212b, and each of i and j is independently 0 or 1;
each R6 is independently H, or a noninterfering substituent, wherein two R6 may optionally form a 5-6 membered ring including the nitrogen to which they are bound;
each R3 is independently a noninterfering substituent;
n is 0-3;
each of L1 and L2 is a linker;
each R4 is independently a noninterfering substituent;
m is 0-4;
Ar is n phenyl group or a thienyl substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring.
2. The compound of claim 1 wherein each R6 is independently H, alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), acyl (1-6C), arylalkyl or arylacyl, or the heteroatom forms of the foregoing, or both R6 are joined to form a ring including the nitrogen to which they are attached which R6 ring may optionally be substituted by alkyl, halo, or alkoxy.
3. The compound of claim 2 wherein both R6 are H or alkyl (1-4C).
4. The compound of claim 2 wherein one R6 is H and the other is acyl.
5. The compound of claim 2 wherein two R6 are joined to form a ring.
6. The compound of claim 2 wherein when one R6 is H, the other R6 is other than 14.
7. The compound of claim 5 wherein said ring is a piperazine ring, a piperidine ring, or a morpholine ring.
8. The compound of claim 1 wherein A is COXjCOR2,
wherein R2 is H, or is straight or branched chain alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, or heteroarylalkyl, each optionally substituted with halo, alkyl, heteroalkyl, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, CONR2, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, or
wherein R2 is OR, NR2, SR, NRCONR2, OCONR2, or NRSO2NR2, wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, and wherein two R attached to the same atom may form a 3-8 member ring and wherein said ring may further be substituted by alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, each optionally substituted with halo, SR, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof wherein two R attached to the same atom may form a 3-8 member ring, optionally substituted as above defined; and X, if present, is alkylene.
9. The compound of claim 8 wherein R2 is NR2.
10. The compound of claim 9
wherein NR2 is selected from the groups consisting of
wherein one R2 is methyl and the other R2 is other than methyl.
11. The compound of claim 10 wherein NR2 is NHCH3, N(CH3)CH2CHCH2 or N(CH3)OCH3.
12. The compound of claim 10 wherein j is 0.
13. The compound of claim 1 wherein L1 is CO, CHOH or CH2.
14. The compound of claim 13 wherein L1 is CO.
15. The compound of claim 1 wherein L2 is alkylene (1-4C) or alkenylene (2-4C).
16. The compound of claim 15 wherein L1 is methylene.
17. The compound of claim 1 wherein Ar is phenyl or thienyl optionally substituted with 0-5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof, and wherein two of said optional substituents on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members.
18. The compound of claim 16 wherein said phenyl or thienyl is unsubstituted or has a single substituent.
19. The compound of claim 18 wherein said optional substituent is halo, OR, or alkyl.
20. The compound of claim 1 wherein R4 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and two of R4 on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members, or R4 is \u2550O or an oxime, oximeether, oximeester or ketal thereof.
21. The compound of claim 20 wherein each R4 is halo, OR, or alkyl.
22. The compound of claim 21 wherein m is 0, 1, or 2.
23. The compound of claim 22 wherein m is 2 and both R4 are alkyl.
24. The compound of claim 1 wherein each R3 is halo, alkyl, heteroalkyl, OCOR, OR, NRCOR, SR, or NR2, wherein R is H, alkyl, aryl, or heteroforms thereof.
25. The compound of claim 24 wherein R3 is halo or alkoxy.
26. The compound of claim 25 wherein n is 0, 1 or 2.
27. The compound of claim 1 wherein L1 is coupled to the \u03b1 ring at the 4-, 5- or 6-position.
28. The compound of claim 1 wherein Z2 at position 3 is CA and the Z2 at position 2 is CH.
29. The compound of claim 1 wherein the compound of formula (1) is selected from the group consisting of:
1-{1-Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R,5 S-dimethyl-piperazine-1-carbonyl -1H-indol-3-yl}-2-pyrrolidin-1-yl-ethane-1,2-dione
2-{1-Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-1H-indol-3-yl}-N-methyl-2-oxo-acetamide
2-( 1-Amino-6-chloro-5-{4-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl1H-indol-3-yl}-2-oxo-acetamide
2-{1-Amino-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-6-methoxy-1H-indol-3-yl}-N,N-dimethyl-2-oxo-acetamide
1-{1-Amino-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-6-methoxy-1H-indol-3-yl}-2-pyrrolidin-1-yl-ethane-1,2-dione
2-{1-Amino-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-6-methoxy-1H-indol-3-yl}-N-methyl-2-oxo-acetamide
1-{1-Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-1H -indol-3-yl}-2-(R-(+)-3-hydroxy-pyrrolidin-1-yl)-ethane-1,2-dione
2-{1-Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-1H-indol-3-yl}-N,N-dimethyl-2-oxo-acetamide
2-{6-Chloro-1-dimethylamino-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-1H-indol-3-yl}-N,N-dimethyl-2-oxo-acetamide
1-{6-Chloro-1-dimethylamino-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-1H-indol-3-yl}-2-(3-hydroxy-pyrrolidin-1-yl)-ethane-1,2-dione
{1-Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-1H-indol-3-yl}-oxo-acetic acid methyl ester
1-{1-Amino-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-6-ethoxy-1H-indol-3-yl}-2-pyrrolidin-1-yl-ethane-1,2-dione
1-{1-Amino-5-4-(3-chloro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-6-ethoxy-1H -indol-3-yl}-2-pyrrolidin-1-yl-ethane-1,2-dione
1-{1-Amino-5-4-(2-chloro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-6-ethoxy-1H-indol-3-yl}-2-pyrrolidin-1-yl-ethane-1,2-dione
2-{1-Amino-6-chloro-5-4-(3-chloro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-1H-indol-3-yl}-2-oxo-acetamide
2-{1-Amino-6-chloro-5-4-(3-chloro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl1H-indol-3-yl}-N-methyl-2-oxo-acetamide
2-{1-Amino-5-4-(3-chloro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-6-ethoxy-1H-indol-3-yl}-N,N-dimethyl-2-oxo-acetamide
1-{1-Amino-6-chloro-5-4-(4-fluoro-benzyl)-trans-2,5-dimethyl-piperazine-1-carbonyl1H-indol-3-yl}-2-pyrrolidin-1-yl-ethane-1,2-dione
1-{1-Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-1H-indol-3-yl}-2-(R-(+)-3-methoxy-pyrrolidin-1-yl)-ethane-1,2-dione
1-{1-Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl1H-indol-3-yl}-2-azetidin-1-yl-ethane-1,2-dione
1-{1Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R-methyl-piperazine-1-carbonyl-1H-indol-3-yl}-2-pyrrolidin-1-yl-ethane-1,2-dione
2-{1Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R-methyl-piperazine-1-carbonyl-1H-indol-3-yl}-N-methoxy-N-methyl-2-oxo-acetamide
1-{1-Amino-6-chloro-5-4-(4-fluoro-benzyl)-2R-methyl-piperazine-1-carbonyl-1H-indol-3-yl}-2-(R-(+)-3-hydroxy-pyrrolidin-1-yl)-ethane-1,2-dione
1-{1-Amino-5-4-(4-fluoro-benzyl)-2R,5S-dimethyl-piperazine-1-carbonyl-6-methyl-1H-indol-3-yl}-2-pyrrolidin-1-yl-ethane-1,2-dione
30. The compound of claim 1 wherein L2 is methylene with an aryl, heterocyclic, alkyl or heteroalkyl substituent.
31. The compound of claim 30 where L2 is methylene with a methyl or phenyl substituent.
32. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and an acceptable pharmaceutical excipient.